Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

161. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding

Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Enns R A, Gagnon Y M, Rioux K P, Levy A R Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology An approach in which an intravenous (i.v.) proton-pump inhibitor (PPI), such as pantoprazole, was administered before endoscopy treatment was examined in patients with upper gastrointestinal (GI) bleeding. Type of intervention

2003 NHS Economic Evaluation Database.

162. Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer

Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Abdulwadud O. Proton pump (...) inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 11 Authors' objectives This aim of this critical appraisal was to assess the effectiveness of proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Ulcer Agents; Peptic Ulcer /drug therapy; Proton Pumps Language Published English Country

2002 Health Technology Assessment (HTA) Database.

163. The efficacy of proton pump inhibitors in adults with functional dyspepsia

The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia Shiau J Y, Shukla V K, Dube C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shiau J Y, Shukla V K, Dube C (...) . The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 30 Authors' objectives Primary objective: To determine the efficacy of PPIs in the reduction of symptoms in adults with functional dyspepsia compared with placebo, prokinetic agents and H2-antagonists. Secondary objectives: - to determine if the effect of PPIs differs between symptom subgroups (dysmotility-like, or ulcer-like) in functional

2002 Health Technology Assessment (HTA) Database.

164. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Salas M, Ward A, Caro J Authors' objectives To compare gastric ulcer healing rates for patients treated (...) with a proton-pump inhibitor (PPI), an histamine 2-receptor antagonist or placebo. Searching MEDLINE, and the Cochrane Library were searched using the following keywords: 'proton pump inhibitors', 'PPI', 'rabeprazole', 'omeprazole' 'esomeprazole', 'lansoprazole' 'pantoprazole', 'ranitidine'; 'healing rates', 'gastric ulcer', 'stomach ulcer', 'gastric ulcer disease', 'peptic ulcer', 'peptic related disorders'; and 'clinical trials', 'randomized clinical trials' and 'multicenter studies'. In addition, medical

2002 DARE.

165. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis

Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Edwards S J, Lind T, Lundell L Authors' objectives To compare the efficacy of lansoprazole with all other proton-pump inhibitors (PPIs) in the maintenance of healed reflux oesophagitis, through a systematic review (...) but who are concerned about the cost implications of prescribing a standard-dose PPI. Reviewer's comment: Two of the authors were from AstraZeneca, the manufacturer of esomeprazole. Research: The authors state that a cost-effectiveness analysis would need to be undertaken to determine whether the increase in effect represents good value for money. Bibliographic details Edwards S J, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. Journal

2002 DARE.

166. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis

Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Plumb J M, Edwards S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of esomeprazole (40 mg), a proton-pump inhibitor (PPI), in the treatment of gastro-oesophageal reflux disease (GORD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients requiring treatment for GORD

2002 NHS Economic Evaluation Database.

167. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Vallve M, Vergara M, Gisbert J P, Calvet X Authors' objectives To compare the efficacy of a single versus double dose of a proton-pump (...) the results of studies of triple therapy using clarithromycin and metronidazole as second-line therapy before recommending otherwise promising schedules (due to concerns about drug resistance in H. pylori status). Bibliographic details Vallve M, Vergara M, Gisbert J P, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Alimentary Pharmacology and Therapeutics 2002; 16(6): 1149-1156 PubMedID Indexing Status Subject indexing

2002 DARE.

168. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand (...) by a grant from AstraZeneca, Molndal, Sweden. Bibliographic details Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. PharmacoEconomics 2002; 20(4): 267-277 PubMedID Other publications of related interest Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different

2002 NHS Economic Evaluation Database.

169. Proton pump inhibitors update

Proton pump inhibitors update Proton pump inhibitors update Proton pump inhibitors update Halas C Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Halas C. Proton pump inhibitors update. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new (...) . Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Digestive System Diseases; Proton Pump Inhibitors Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu

2001 Health Technology Assessment (HTA) Database.

170. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms

Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Raisch D W, Klaurens L M, Hayden C, Malagon I, Pulliam G, Fass R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two proton-pump inhibitors, lansoprazole and omeprazole, were studied. No further details were given. Type of intervention Other: Impact of a formulary change that concerned treatments. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients in the study setting who

2001 NHS Economic Evaluation Database.

171. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori (...) infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Janssen M J, Van Oijen A H, Verbeek A L, Jansen J B, De Boer W A Authors' objectives To evaluate whether there is a difference in the efficacy between triple therapies with proton-pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus clarithromycin and either amoxicillin or a nitroimidazole, for the treatment of Helicobacter pylori (H. pylori) infection. Searching

2001 DARE.

172. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

173. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers

Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Zed P J, Loewen P S, Slavik R S, Marra C A Authors' objectives To evaluate the efficacy of proton-pump inhibitors (PPIs), compared with placebo and histamine-receptor antagonists (H2RAs), for reducing the incidence of rebleeding, surgery and death in acute (...) gastrointestinal bleeding (GIB) associated with peptic ulcer disease. Searching MEDLINE, EMBASE and PREMEDLINE were searched systematically from 1966 to September 2000 for literature in the English language. The search terms included 'gastrointestinal', 'bleeding', 'hemorrhage', 'proton-pump inhibitor', 'omeprazole', 'pantoprazole', 'lansoprazole' and 'rebeprazole'. A manual search of the references from retrieved studies was also performed. Study selection Study designs of evaluations included in the review

2001 DARE.

174. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer

Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Gisbert J P, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares J M Authors' objectives To evaluate whether proton-pump inhibitors are more effective than H2 (...) -antagonists (H2-A) for the treatment of bleeding peptic ulcer. Searching MEDLINE (via PubMed) was searched up to January 2000 using the keywords 'bleeding', 'proton pump inhibitor', 'peptic ulcer, and each of the drug names. The references of reviews and the retrieved articles were also examined. Study selection Study designs of evaluations included in the review Only randomised controlled trials (RCTs) were eligible. Specific interventions included in the review Trials that compared an H2-A (cimetidine

2001 DARE.

175. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis

Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Edwards S J, Lind T, Lundell L Authors' objectives To compare the effectiveness of esomeprazole with the recommended dose of proton-pump inhibitors (PPIs) in the healing of reflux oesophagitis, using omeprazole as a common (...) research and practice. Bibliographic details Edwards S J, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Alimentary Pharmacology and Therapeutics 2001; 15(11): 1729-1736 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Administration, Oral; Dose-Response Relationship, Drug; Enzyme Inhibitors /pharmacology; Esomeprazole; Esophagitis, Peptic /drug therapy; Humans; Omeprazole /analogs & Proton Pump Inhibitors; Randomized

2001 DARE.

176. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. (Abstract)

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Heartburn affects 25% of the adult population on a monthly basis and represents the core symptom of gastro-oesophageal reflux disease (GORD). Treatment is readily available and puts a large demand on healthcare budgets. Research in the past has focused largely on the treatment of oesophagitis. A majority of GORD (...) patients show no endoscopic abnormalities and in daily practice most patients are treated empirically.Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in the empirical treatment of GORD and the treatment of endoscopy negative reflux disease (ENRD).Electronic searches were performed of the Cochrane Controlled Trials Register, MEDLINE and EMBASE. Bibliographies were screened.Included were randomised

2000 Cochrane

177. Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia

Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Clinical Excellence. Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 7. 2000 Authors' objectives To provide guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. Authors' conclusions Guidance 1.1 In patients with documented duodenal or gastric ulcers, a treatment strategy of testing for Helicobacter pylori and, where positive, eradicating the infection

2000 Health Technology Assessment (HTA) Database.

178. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating (...) ', 'clarithromycin', 'amoxycillin', 'omeprazole', 'lansoprazole', 'pantoprazole', 'proton pump inhibitor' and 'triple' (titles). Additional material was obtained by examining references of retrieved articles and reviews on H. pylori treatment, and by manually searching abstracts submitted to the American Gastroenterological Association congresses (1995 to 1998) and the European Helicobacter pylori Study Group congresses on H. pylori treatment (1996 to 1998). Study selection Study designs of evaluations included

2000 DARE.

179. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori

Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Gisbert J P, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares J M Authors (...) ' objectives To compare two twice-daily (b.d.), one-week triple therapies for Helicobacter pylori eradication by conducting a meta-analysis. The two therapies were a combination of a proton-pump inhibitor (PPI), clarithromycin (C) and amoxycillin (A), and a combination of PPI, C and a nitroimidazole (N). Searching The authors searched PubMed up to September 1999 (the start date was unclear). Abstracts from the International Workshop on Gastroduodenal Pathology and Helicobacter pylori, and American

2000 DARE.

180. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies van Oijen A H, Verbeek A L, Jansen J B, de Boer W A Authors' objectives (...) To compare treatment of Helicobacter pylori infection with ranitidine bismuth citrate- and proton pump inhibitor-based triple therapies. Searching The authors searched MEDLINE and Current Contents, and manually reviewed abstracts submitted to meetings of the American Gastroenterological Association (Digestive Disease and the United European Gastroenterology weeks) and the European Helicobacter Study Group, for the period 1996 to 1999. Study selection Study designs of evaluations included in the review

2000 DARE.